Product details
Semax
Save $8.98 per unit with current offers
Explore Semax amounts, pricing, and product information.
Select your product
10mg · 1 unit · Total
$20.97 per unit
Save $8.98 total
WINTER30 −30%
Save your selection in the cart. Ordering is not open. Contact us for availability.
For laboratory research only. Not for human or veterinary use. Research-use policy.
Know your compound
Compound information
Semax
The Semax molecular reference is indexed under ACTH (4-7), Pro-Gly-Pro-.
Identity references 1 source
- Catalog identity
- SEMAX
- Intended use
- Laboratory research
- Reference molecule
- ACTH (4-7), Pro-Gly-Pro-
- PubChem record
- CID 9811102
- Molecular formula
- C37H51N9O10S
- Molecular weight
- 813.9 g/mol
Molecular data describe the reference compound in PubChem, not a laboratory analysis of this product or batch.
Primary literature
Verified research references
Primary-source bibliography for the named compound. These studies did not test this catalog item.
Human research included
Semax2 verified references
Identity note
The cited literature names Semax as a study intervention; that name correspondence does not establish the identity, composition, formulation, quality, or equivalence of the PropeptIQ catalog material.
[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].
Gusev EI · 1997 · Zh Nevrol Psikhiatr Im S S Korsakova
- Study design
- Human interventional study
- Research context
- Human research
- Sample size
- 110 participants or samples
- Study population
- 30 patients in the acute period of hemispheric ischemic stroke and 80 conventionally treated controls; random allocation and blinding are not stated in the indexed abstract.
PMID: 11517472
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Gusev EI · 2018 · Zh Nevrol Psikhiatr Im S S Korsakova
- Study design
- Human interventional study
- Research context
- Human research
- Sample size
- 110 participants or samples
- Study population
- 110 patients after ischemic stroke, divided by rehabilitation timing and receipt of Semax; the indexed abstract does not specify randomization or blinding.
PMID: 29798983
DOI: 10.17116/jnevro20181183261-68
Bibliographic references do not establish the identity, purity, safety, effectiveness, or suitability of this catalog item and are not use guidance. For legitimate laboratory and research use only; not for human or veterinary use.
Related catalog
